FINOVAX TECHNOLOGIES H-1B Visa Sponsorship & Salary Data

The median H-1B salary at FINOVAX TECHNOLOGIES is $102,710, based on 37 certified filings from FY 2023 to FY 2026. This is 14% lower than the national H-1B median salary of $120,000. Compensation at FINOVAX TECHNOLOGIES reflects their market positioning, with entry-level roles starting around $82,763 and senior positions reaching $131,997 or higher. These figures represent base salaries in LCA filings and may not include bonuses, equity grants, or other compensation common at large employers.

Salaries at FINOVAX TECHNOLOGIES range from $60,715 at the 10th percentile to $131,997 at the 90th percentile, showing a $71,282 spread across experience levels and roles. The 25th percentile is $82,763 and the 75th percentile is $108,306.

Yes, FINOVAX TECHNOLOGIES actively sponsors H-1B visas in FY 2026. In the most recent fiscal year (FY 2026), FINOVAX TECHNOLOGIES filed 4 H-1B labor condition applications with 4 certified and 0 denied, at a median salary of $82,930. Across FY 2023–2026, they have filed 37 total H-1B applications with 37 certified and a 0% lifetime denial rate, demonstrating ongoing commitment to hiring international talent. FINOVAX TECHNOLOGIES sponsors positions across multiple job categories and locations, making them a viable option for professionals seeking H-1B visa sponsorship.

In the most recent fiscal year (FY 2026), FINOVAX TECHNOLOGIES filed 4 H-1B applications, with 4 certified and 0 denied. Over 4 years of data, FINOVAX TECHNOLOGIES has consistently demonstrated commitment to H-1B sponsorship.

Note: These are Labor Condition Applications (LCAs) filed with the Department of Labor, which is a prerequisite for H-1B petitions. The actual number of H-1B petitions filed with USCIS may differ.

FINOVAX TECHNOLOGIES's LCA (Labor Condition Application) denial rate is 0%, with 0 out of 37 applications denied across all years. This translates to a 100.0% certification rate, which indicates how successfully the company prepares and files H-1B applications. A lower denial rate suggests better compliance with Department of Labor requirements, proper wage documentation, and accurate job classification. Prospective H-1B applicants should consider this approval rate alongside other factors like salary, job role, and location when evaluating FINOVAX TECHNOLOGIES as a potential H-1B sponsor.

This is an excellent approval rate, indicating FINOVAX TECHNOLOGIES has strong H-1B sponsorship practices and typically meets DOL requirements. Applicants can feel confident in the company's H-1B track record.

FINOVAX TECHNOLOGIES sponsors H-1B visas for various specialty occupation positions requiring at least a bachelor's degree. Based on 37 certified filings, the most commonly sponsored job titles reflect the company's primary business functions and talent needs. These positions typically require specialized knowledge in fields like technology, engineering, finance, or scientific research. Understanding which roles FINOVAX TECHNOLOGIES most frequently sponsors can help job seekers target their applications effectively.

Most common H-1B job titles at FINOVAX TECHNOLOGIES:

The most frequently sponsored role is Business Intelligence Analyst with 22 filings at a median salary of $108,306. This is followed by Software Developer (5 filings) and Market Research Analyst.

FINOVAX TECHNOLOGIES's H-1B positions are distributed across multiple U.S. locations, with concentration in major metropolitan areas and tech hubs. Geographic distribution often reflects company office locations, client sites, and regional market demands. Location significantly impacts H-1B salary due to varying cost of living and local wage requirements. Understanding where FINOVAX TECHNOLOGIES sponsors H-1B workers can help candidates target specific offices and negotiate appropriate compensation for each market.

Top FINOVAX TECHNOLOGIES H-1B locations:

The largest H-1B hub for FINOVAX TECHNOLOGIES is New York, NY with 6 filings at a median salary of $108,306. The highest-paying location is San Francisco, CA at $145,600 median. Salaries range from $60,715 to $145,600 across office locations.

FINOVAX TECHNOLOGIES's median H-1B salary has changed by -23% from FY 2023 ($108,306) to FY 2026 ($82,930). Tracking salary trends over time reveals how FINOVAX TECHNOLOGIES adjusts compensation to remain competitive in the H-1B labor market. Salary growth typically reflects inflation adjustments, increased demand for specialized skills, and evolving prevailing wage requirements. These historical trends can help applicants understand future salary expectations and negotiate appropriately when considering H-1B opportunities at FINOVAX TECHNOLOGIES.

Year-by-year breakdown:

• FY 2023: $108,306 (6 certified)
• FY 2024: $108,306 (16 certified)
• FY 2025: $82,763 (11 certified)
• FY 2026: $82,930 (4 certified)

Salary levels have remained relatively stable at FINOVAX TECHNOLOGIES.

FINOVAX TECHNOLOGIES primarily files H-1B applications at Wage Level II, accounting for 73% of their filings. DOL wage levels range from Level I (entry-level, 17th percentile of local wages) to Level IV (expert, 67th percentile). Wage level determines both salary requirements and, under recent H-1B rules, lottery selection priority. Higher wage levels receive preference in the H-1B lottery, making FINOVAX TECHNOLOGIES's wage level distribution an important factor for prospective applicants assessing their chances of H-1B selection.

FINOVAX TECHNOLOGIES has a mix of entry-level (Level I) and experienced (Level II+) H-1B positions. This reflects a range of roles from junior to senior.

FINOVAX TECHNOLOGIES's median H-1B salary of $102,710 is 14% lower than the national H-1B median of $120,000 across all employers and industries. This comparison provides context for evaluating FINOVAX TECHNOLOGIES's competitiveness in attracting H-1B talent. Keep in mind that industry, location, and job function significantly impact salary levels. Tech companies and financial institutions typically offer higher H-1B salaries than other sectors, while salaries in major metros like San Francisco and New York exceed those in smaller markets. Compare FINOVAX TECHNOLOGIES's offerings with similar companies in your field for a more accurate assessment.

FINOVAX TECHNOLOGIES's H-1B salaries are below the national median, though this may vary significantly by role, experience level, and location. Consider researching specific positions for more accurate compensation expectations.

Recent H-1B rule changes have increased filing fees and introduced wage-level prioritization in the lottery. FINOVAX TECHNOLOGIES files 27% of positions at Level I, which may face more lottery competition under wage-level prioritization rules.

With 37 certified filings, FINOVAX TECHNOLOGIES invests significantly in H-1B sponsorship. The company's 0% denial rate suggests strong compliance with H-1B requirements and documentation standards.

Note: H-1B regulations are subject to change. Fees shown are estimates based on 2024 USCIS fee schedules. Actual costs may vary based on company size, premium processing, and future rule changes.